|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Polysaccharides from the root of Angelica sinensis promotes hematopoiesis and thrombopoiesis through the PI3K/AKT pathway 显示文摘 | LIU Chang Ll Jianqin MENG Fanyi | 2010 | BMC Complem Altern M2010，10，1： | 1 |
| 2 | Low re fractive metamaterials for gain enhancement of hom antenna 显示文摘 | WU Qun PAN Pan MENG Fanyi | 2007 | Appl Phys: A2007，87，2： | 1 |
| 3 | Controllable meta- material-loaded waveguides supporting backward and forward waves显示文摘 | Meng Fanyi Wu Qun Erni Daniel | 2011 | IEEE Transactions on Antennas and Propagation2011，59，9： | 1 |
| 4 | A Method of Using Nonidentical Resonant Coils for Frequency Splitting Elimination in Wireless Power Transfer显示文摘 | Lyu Yuelong Meng Fanyi Yang Guohui | 2015 | IEEE Transactions on Power Electronics2015，30，11： | 1 |
| 5 | Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2显示文摘 | Ling Jiang Guopan Yu Wei Meng Zhixiang Wang Fanyi Meng Wenli Ma | 2013 | Tumor Biology2013，，2： | 1 |
| 6 | gtate of the Art in Passive Bandpass Filter Solutions for 60 GHz Communications显示文摘 | XU Shanshan MENG Fanyi MA Kaixue YEO Kiat Seng | 2016 | ZTE Communications2016，14，B12： | 0 |
| 7 | An Open-Label Study of Pegylated Liposomal Doxorubicin,Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese Population显示文摘OBJECTIVE Though doxorubicin is highly activein the treatment of multiple myeloma, its toxicityprofile limits its therapeutic index. We performed thisstudy to evaluate the efficacy and safety of pegylatedliposomal doxorubicin (PLD, Caelyx^(?)), vincristine,and reduced-dose dexamethasone combinationtherapy in newly diagnosed multiple myeloma (MM)patients in a Chinese population.METHODS This was an open-label, single-armstudy in which newly diagnosed patients with MMreceived PLD 40 mg/m^2 intravenously on Day 1,vincristine 1.4 mg/m^2 intravenously (maximum 2 mg)on Day 1, and 40 mg of dexarnethasone (intravenouslyor orally) from Day 1 to Day 4. Treatment wasrepeated every 28 days for at least 4 cycles.RESULTS In the intent-to-treat (ITT) analysis, theoverall response rate was 68.29%, and the completeremission rate was 10.98%. The incidence of alladverse events was 46.34%. The most commonnon-hematologic toxicities were palmar-plantarerythrodysesthesia (13.4%) and stomatitis (6.1%).CONCLUSION PLD, vincristine, and a reduceddosedexamethasone combination (DVd) is aneffective and safe regimen in newly diagnosed MMpatients in a Chinese population. | Yang Shen Zhixiang Shen Bin Jiang Jian Hou Rong Zhan Lugui Qiu Daobin Zhou Jie Jin Juan Li Fanyi Meng Ping Zou Ting Liu Jianyong Li Chun Wang Depei Wu Jun Ma | 2009 | Clinical oncology and cancer resexreh2009，6，6： | 0 |
| 8 | Devising optimal integration test orders using cost-benefit analysis显示文摘Integration testing is an integral part of software testing.Prior studies have focused on reducing test cost in integration test order generation.However,there are no studies concerning the testing priorities of critical classes when generating integration test orders.Such priorities greatly affect testing efficiency.In this study,we propose an effective strategy that considers both test cost and efficiency when generating test orders.According to a series of dynamic execution scenarios,the software is mapped into a multi-layer dynamic execution network(MDEN)model.By analyzing the dynamic structural complexity,an evaluation scheme is proposed to quantify the class testing priority with the defined class risk index.Cost–benefit analysis is used to perform cycle-breaking operations,satisfying two principles:assigning higher priorities to higher-risk classes and minimizing the total complexity of test stubs.We also present a strategy to evaluate the effectiveness of integration test order algorithms by calculating the reduction of software risk during their testing process.Experiment results show that our approach performs better across software of different scales,in comparison with the existing algorithms that aim only to minimize test cost.Finally,we implement a tool,ITOsolution,to help practitioners automatically generate test orders. | Fanyi MENG Ying WANG Hai YU Zhiliang ZHU | 2022 | Frontiers of Information Technology & Electronic Engineering2022，23，5： | 0 |
| 9 | Design and Analysis of a 0.01-to-6GHz 31dBm-P1dB 31.5%-PAE Distributed Power Amplifier in 0.25-μm GaAs Technology显示文摘This paper presents the design and analysis of a distributed power amplifier with 6-dB bandwidth from 10MHz to 6GHz.To meet the stringent targeted specification,the concurrent design and analysis are carefully performed with optimizations in both passive and active devices.The gate capacitive division technique is proposed and proven theoretically of bandwidth extension effect and power efficiency enhancement.To validate the theory,a prototype is designed in a 0.25-µm GaAs technology.The fabricated amplifier chip is packaged in an evaluation cavity of SMA connectors.The measurement shows an average power gain of 15dB,OP1dB and PSAT of 31dBm and 32.6dBm at 3GHz,and PAE at OP1dB and PSAT points are 31.5% and 43.7% respectively.To the best of authors’knowledge,the amplifier achieves the highest Power-added efficiency(PAE)among the similar GaAs amplifiers. | MENG Fanyi LIU Cha HU Jianquan MOU Shouxian MA Kaixue | 2021 | Chinese Journal of Electronics2021，30，3： | 0 |
| 10 | An Advanced Approach for Improving the Prediction Accuracy of Natural Gas Price显示文摘As one of the most important commodity futures,the price forecasting of natural gas futures is of great signifi-cance for hedging and risk aversion.This paper mainly focuses on natural gas futures pricing which considers seasonalityfluctuations.In order to study this issue,we propose a modified approach called six-factor model,in which the influence of seasonalfluctuations are eliminated in every random factor.Using Monte Carlo method,wefirst assess and comparative analyze thefitting ability of three-factor model and six-factor model for the out of sample data.It is found that six-factor model has better performance than three-factor model and natural gas futures prices is strongly influenced by winter effect.We then apply the proposed model to predict the price of natural gas futures in the year 2019.It is found that natural gas prices have a weak upward trend in the coming year and are relatively volatile in winter. | Quanjia Zuo Fanyi Meng Yang Bai | 2021 | Energy Engineering2021，118，2： | 0 |
| 11 | Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib:efficacy and safety显示文摘Dasatinib is a highly effective second-generation tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML).In 2007,a pivotal phase-2 study of dasatinib as second-line treatment was initiated in 140 Chinese CML patients.This report from the 4-year follow-up revealed that 73% of 59 patients in chronic phase (CML-CP) and 32% of 25 patients in accelerated phase (CML-AP) remained under treatment.The initial dosage of dasatinib for CML-CP and CML-AP patients were 100 mg once daily and 70 mg twice daily (total=140 mg/ day),respectively.The cumulative major cytogenetic response (MCyR) rate among patients with CML-CP was 66.1%(versus 50.8% at 18 months),and the median time to MCyR was 12.7 weeks.All CML-CP patients who achieved MCyR after a 4-year follow-up also achieved a complete cytogenetic response.The cumulative complete hematological response (CHR) rate among patients with CML-AP was 64%(16/25),with three CML-AP patients achieving CHR between 18 months and 4 years of follow-up;the median time to CHR was 16.4 weeks.The adverse event (AE) profile of dasatinib at 4 years was similar to that at 6 and 18 months.The most frequently reported AEs (any grade) included pleural effusion,headache,and myelosuppression.These long-term follow-up data continue to support dasatinib as a second-line treatment for Chinese patients with CML. | Xiaojun Huang Qian Jiang Jianda Hu Jianyong Li Jie Jin Fanyi Meng Zhixiang Shen Ting Liu Depei Wu Jianmin Wang Jianxiang Wang | 2019 | Frontiers of Medicine2019，13，3： | 0 |
| 12 | Autologous peripheral hematopoietic stem-cell transplantation in a patient with refractory pemphigus显示文摘The aim of this study is to explore the effective-ness of autologous peripheral hematopoietic stem-cell transplantation in the treatment of refractory pemphigus.A 35-year-old male patient presented with a 4-year history of recurrent bullae on his trunk and extremities.The dia-gnosis of pemphigus was made on the basis of the clinical,histologic and immunofluorescence findings.The patient had shown resistance to conventional therapy with gluco-corticoid and immunosuppressive agents.Two months before admission,he complained of hip joint pain.X-ray and CT scan revealed aseptic necrosis of the femoral head.Stem-cell mobilization was achieved by treatment with cyclophosphamide,granulocyte colony-stimulating factor(G-CSF)and rituximab.Peripheral blood stem cells were collected via leukapheresis and cryopreserved for later use.Immunoablation was accomplished by using cyclophospha-mide(200 mg/kg;divided into 50 mg/kg on days-5,-4,-3,and-2),antithymocyte globulin(ATG;10 mg/kg;divided into 2.5 mg/kg on days-6,-5,-4,and-3),and rituximab(1200 mg/d;divided into 600 mg/d on days 0 and 7).Autologous peripheral hematopoietic stem cell transplanta-tion was followed by reconstitution of the immune system which was monitored by flow cytometry.The glucocorti-coid was withdrawn immediately after transplantation.The pemphigus titer turned negative 6 weeks after transplanta-tion and remained negative.The patient was in complete drug-free remission with no evidence of residual clinical or serological activity of pemphigus during 1 year of follow-up.The patient’s response suggests that autologous peri-pheral hematopoietic stem cell transplantation may be a potential“cure”for refractory pemphigus.However,fur-ther studies are needed to evaluate the risk-benefit ratio of this approach in patients with pemphigus showing resist-ance to conventional therapy. | Ledong SUN Jing SUN Kang ZENG Fanyi MENG Youtao DIAO Dan XU Liang HUANG Jie ZHAO Qifa LIU | 2008 | Frontiers of Medicine2008，2，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员